UK’s NICE wants more effectiveness data on Lilly’s tirzepatide

The Unit­ed King­dom’s Na­tion­al In­sti­tute for Health and Care Ex­cel­lence (NICE) is ask­ing Eli Lil­ly for more da­ta about tirzepatide be­fore it will rec­om­mend the type 2 di­a­betes drug’s use.

NICE said Tues­day in draft guid­ance that it has not rec­om­mend­ed the drug as a treat­ment for type 2 di­a­betes in adults. It asked Eli Lil­ly to pro­vide more da­ta to ad­dress “un­cer­tain­ties” in clin­i­cal ev­i­dence and how the drug com­pares to oth­er treat­ments for type 2 di­a­betes.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN